NCT06907017招募中不适用
First In Human Clinical Study of the CorWave Left Ventricular Assist System for the Treatment of Patients With Advanced Heart Failure
CorWave3 个研究点 分布在 2 个国家目标入组 20 人开始时间: 2025年5月6日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 3
- 主要终点
- Survival post-implant
研究概览
简要总结
The study is a prospective, multi-center, non-randomized trial to evaluate the safety and effectiveness of the CorWave LVAS for the treatment of advanced heart failure patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject or legal representative has signed Informed Consent Form
- •Age > 18 and < 75 years old
- •Body Surface Area (BSA) ≥ 1.2 m2
- •Left Ventricular Ejection Fraction (LVEF) ≤ 35%
- •Inotrope dependent OR
- •Cardiac Index (CI) < 2.2 L/min/m2, while not on inotropes and subjects must also meet one of the following criteria:
- •On Guideline Directed Medical Therapy (GDMT) for at least 45 out of the last 60 days and are failing to respond.
- •Advanced heart failure (Class III or Class IV for at least 14 days AND support from short term mechanical circulatory support for up to 7 days).
- •Females of childbearing age must agree to use adequate contraception.
- •Patient must be eligible for heart transplantation.
排除标准
- •Heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy.
- •Technical obstacles which pose an inordinately high surgical risk, in the judgment of the Investigator
- •Ongoing mechanical circulatory support (MCS) other than IABP or micro axial pumps
- •INTERMACS Class I patients
- •Subject is on a ventilator
- •Subject is pregnant or breastfeeding
- •Presence of a mechanical aortic valve that will not be converted to a bioprosthesis at the time of LVAD implant
- •History of any organ transplant
- •Platelet count < 100,000/μl
- •Psychiatric disease/disorder, illicit drug use, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAD management
- •History of confirmed untreated abdominal aortic aneurysm (AAA) > 5 cm in diameter within 6 months of enrollment
- •Presence of an active, uncontrolled infection
- •Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy the investigator will require based upon the patient's health status
- •Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:
- •An INR ≥ 2.0 not due to anticoagulation therapy
- •Total bilirubin > 43 µmol/L (2.5 mg/dL), liver function tests greater than 3 times the establish laboratory normal, including Serum Albumin below 3.5 g/dl, shock liver, or biopsy proven liver cirrhosis
- •History of severe chronic obstructive pulmonary disease (COPD) and restrictive disease (fibrosis); FEV1 < 50%, a total FEV1 below 1000 mL and a DLCO < 50% predicted.
- •Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention
- •History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (> 50%) uncorrected carotid stenosis
- •Serum creatinine ≥ 221 µmol/L (2.5 mg/dL) or the need for chronic renal replacement therapy.
- •Ongoing patient malnutrition evidenced by nonintentional weight loss of greater than 5% of body mass in the previous 30 days, prealbumin < 16 mg/dL, or Mini Nutritional Assessment score <
- •Poorly controlled diabetes mellitus or a hemoglobin A1c > 8.5%.
- •Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration.
- •Patient has severe aortic insufficiency without plans for correction during pump implant.
- •Planned Bi-VAD support prior to enrollment.
- •Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia.
- •Participation in any other clinical investigation that is likely to confound study results or affect the study.
- •Any condition other than HF that could limit survival to less than 12 months.
- •Acute myocardial infarction within 14 days of implant as diagnosed by ST elevation (STEMI) changes on ECG, diagnostic biomarkers, and hemodynamic abnormalities. Planned or carried out coronary revascularizations (including PCI requiring (dual) antiplatelet therapies).
- •Pulmonary embolus within 6 weeks of implant as documented by computed tomography (CT) scan or nuclear scan.
- •Subject is unwilling or unable to comply with trial requirements.
研究组 & 干预措施
Subjects implanted with CorWave LVAD
Experimental
干预措施: LVAS (Device)
结局指标
主要结局
Survival post-implant
时间窗: 30 days
Survival at 30 days post index procedure.
Freedom from adverse events associated with CorWave LVAD
时间窗: 30 days
Freedom from adverse events associated with the use of the CorWave LVAD through 30 days post LVAD implant defined as non-surgical bleeding, infection, disabling stroke and pump malfunction, as defined by INTERMACS.
次要结局
- Overall survival(up to 2 years)
- Freedom from non-surgical bleeding(180 days)
- Freedom from infection(180 days)
- Freedom from debilitating stroke(180 days)
- Neurocognitive function(up to 2 years)
- Functional status(up to 2 years)
- Adverse Events rates(up to 2 years)
- Health-related Quality of Life(up to 2 years)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
不适用
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery DiseaseSuperficial Femoral Artery StenosisPopliteal Artery StenosisNCT06410313Medinol Ltd.30
终止
不适用
A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart FailureCardio-Renal SyndromeHeart FailureNCT02772146Triomed AB2
Unknown
不适用
Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaGlaucomaNCT03639870Glaukos Corporation65
已完成
不适用
BIOLUX P-I First in Man StudyVascular DiseasePeripheral Artery DiseaseAtherosclerosisArteriosclerosisNCT01221610Biotronik AG60
进行中（未招募）
1 期
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursRenal Cell CarcinomaMetastatic Colorectal CarcinomaHead and Neck Squamous Cell CarcinomaPancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerGastric CancerNon-small Cell Lung CancerNCT06147037AstraZeneca13